The NSCLC Content Hub Channel
2023 Best of Lung: Targeted Therapies in Lung Cancer
July 16, 2024 • NSCLC Content Hub
This video features a presentation at the Best of Lung 2023 conference. Jaime Schneider, MD discusses the latest advancements in targeted therapies for lung cancer. They highlight the…
Therapeutic Advances in Targeting HER2 Alterations in NSCLC & Remaining Challenges
July 12, 2024 • NSCLC Content Hub
Dr. Nicolas Girard, MD, PhD, explores new treatments for advanced HER2-positive non-small cell lung cancer (NSCLC). Highlighting the challenges faced by this orphan patient group, he discusses the…
Recent Videos in NSCLC Content Hub
Lung Cancer Weird Signs and Symptoms | Paraneoplastic Syndromes of Lung Cancer
June 12, 2024 • NSCLC Content Hub
Explore the atypical signs and symptoms of lung cancer, including the rare paraneoplastic syndromes caused by the disease. Learn about small cell carcinoma’s manifestations like Lambert-Eaton myasthenic syndrome,…
Understanding NSCLC Treatment When You Have a KRAS Mutation
May 30, 2024 • NSCLC Content Hub
Learn about the specifics of treating non-small cell lung cancer (NSCLC) when a KRAS mutation is present. The KRAS gene, often mutated in several cancers including NSCLC, signals…
ADC’s for the Treatment of NSCLC
May 22, 2024 • NSCLC Content Hub
This presentation delves into the pathophysiology of CML, highlighting its progression from the chronic phase through the accelerated phase to the blast phase.…
Dr. Socinski on Recommendations for Molecular Testing in Lung Cancer
August 11, 2020 • NSCLC Content Hub
Mark A. Socinski, MD, executive medical director at AdventHealth Cancer Institute, recommends immediate comprehensive molecular testing at the time of lung cancer diagnosis. Stating that oncogenic driver mutation…
Dr. Bertino on Frontline Dacomitinib in Metastatic EGFR+ NSCLC
August 4, 2020 • NSCLC Content Hub
Erin M. Bertino, MD, medical oncologist at Ohio State University Comprehensive Cancer Center – James, provides a comparison of newly approved drug dacomitinib versus the other available FDA-approved…
Importance of Biomarker Testing for RET in Non Small Cell Lung Cancer
July 29, 2020 • NSCLC Content Hub
Jessica Bauman, MD, assistant professor of hematology/oncology at Fox Chase Cancer Center, discusses recent advancements in non-small cell lung cancer (NSCLC) treatment using targeted RET-fusion mutation therapies. RET-fusion…
Dr. Rotow on the Implications of Next-Generation ALK Inhibitors in NSCLC
July 15, 2020 • NSCLC Content Hub
Julia Rotow, MD, medical oncologist at Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, reviews new treatment options for non-small cell lung cancer (NSCLC) patients. Dr. Rotow…